Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Researchers at the Ragon Institute have made a significant discovery about how antibodies can directly enhance the body's ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Pharmacists play a crucial role in managing treatment with chimeric antigen receptor T-cell therapy and bispecific antibodies, focusing on patient selection and side effects, explained Eileen Peng, ...

The U.S. Food and Drug Administration has approved the humanized monoclonal antibody, Zynyz, (retifanlimab-dlwr) as the first ...

New research from the University of Cincinnati demonstrates how specially engineered bacteria taken orally can operate as a ...

These modifications not only enhance the cytotoxic activity of antibodies but also improve their therapeutic potential in cancer treatment. In recent years, the introduction of novel payloads such as ...